Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed metastatic solid tumor * Disease progressed during at least one standard therapy OR has a disease for which there is no standard therapy * No squamous cell carcinoma of the lung * Asymptomatic brain metastases allowed provided both of the following criteria are met: * Brain metastases were treated ≥ 6 months ago * Brain metastases are clinically stable without steroid treatment for 1 week * No clinically relevant pleural effusions or ascites that cannot be controlled by drainage (group 2) PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Hemoglobin ≥ 9.0 g/dL * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN * INR \< 1.5 or PT/PTT normal * Creatinine clearance ≥ 45 mL/min * Negative serum pregnancy test * Fertile patients must use effective contraception during and for at least 2 weeks after completion of study treatment * No New York Heart Association class III or IV congestive heart failure * No unstable angina (anginal symptoms at rest) or new onset angina (within the past 3 months) * No myocardial infarction within the past 6 months * No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * No uncontrolled hypertension, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg, despite optimal medical management * No known severe hypersensitivity to sorafenib tosylate or any its excipients, etoposide, pemetrexed disodium, cisplatin, or carboplatin * No known HIV infection * No chronic hepatitis B or C * No active clinically serious infection \> CTCAE grade 2 * No thrombotic or embolic events, such as cerebrovascular accident or transient ischemic attacks, within the past 6 months * No pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks * No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks * No serious non-healing wound, ulcer, or bone fracture * No evidence or history of bleeding diathesis or coagulopathy * No condition that impairs the patient's ability to swallow whole pills * No malabsorption problem, uncontrolled inflammatory bowel disease, or gastrointestinal disorder causing ≥ 5 bowel movements in a 24-hour period * No significant traumatic injury within the past 4 weeks * Able to take vitamin B12 supplementation and folic acid (group 2) PRIOR CONCURRENT THERAPY: * More than 4 weeks since prior major surgery or open biopsy * No more than 3 prior cytotoxic therapies for metastatic disease * No concurrent St. John's wort or rifampin * No non-steroidal anti-inflammatory drugs (NSAIDs) for 2 days before (5 days for long-acting NSAIDs), during, and for 2 days after pemetrexed disodium administration (group 2) * Concurrent anticoagulation treatment with warfarin or heparin allowed